BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.
Market Dynamics
Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.
However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.
Key features of the study:
- This report provides in-depth analysis of the global BRAF kinase inhibitors market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global BRAF kinase inhibitors market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global BRAF Kinase Inhibitors Market, By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- Global BRAF Kinase Inhibitors Market, By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- Global BRAF Kinase Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global BRAF Kinase Inhibitors Market, By Region:
- North America
- By Country:
- By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
-
- Hoffmann-La Roche AG*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis International AG
- Pfizer, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
